Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
R. Landovitz, D. Donnell, M. Clement, B. Hanscom, L. Cottle, L. Coelho, R. Cabello, S. Chariyalertsak, Eileen F. Dunne, I. Frank, Jorge A Gallardo-Cartagena, A. Gaur, P. Gonzales, H. Tran, J. Hinojosa, E. Kallás, Colleen F. Kelley, M. Losso, J. Madruga, K. Middelkoop, N. Phanuphak, B. Santos, O. Sued, Javier Valencia Huamaní, E. Overton, S. Swaminathan, C. del Rio, R. Gulick, P. Richardson, P. Sullivan, E. Piwowar-Manning, M. Marzinke, C. Hendrix, Maoji Li, Zhe Wang, J. Marrazzo, E. Daar, A. Asmelash, T. Brown, P. Anderson, S. Eshleman, Marcus Bryan, Cheryl Blanchette, J. Lucas, C. Psaros, S. Safren, J. Sugarman, Hyman Scott, J. Eron, Sheldon D. Fields, N. Sista, K. Gomez-Feliciano, A. Jennings, Ryan Kofron, T. Holtz, Katherine Shin, J. Rooney, Kimberly Smith, W. Spreen, D. Margolis, A. Rinehart, A. Adeyeye, M. Cohen, M. McCauley, B. Grinsztejn
New England Journal of Medicine